Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Rexahn Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 75,000 75,000 0 0 0
Cost of Goods Sold (COGS) incl. D&A 41,604 50,659 45,070 42,386 37,133
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 41,604 50,659 45,070 42,386 37,133
Depreciation - - 45,070 42,386 37,133
Amortization of Intangibles - - 0 0 0
Gross Income 33,396 24,341 (45,070) (42,386) (37,133)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - - 16.09M 6.11M 7.94M
Research & Development - - 11.99M 3.39M 3.25M
Other SG&A - - 4.09M 2.71M 4.69M
Other Operating Expense - - 0 431,099 0
Unusual Expense - - (4.78M) (331,768) 1.37M
EBIT after Unusual Expense - - 4.78M 331,768 (1.37M)
Non Operating Income/Expense - - (101,627) 0 (204,212)
Non-Operating Interest Income - - 109,240 21,092 49,280
Equity in Affiliates (Pretax) - - 0 0 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized - - 0 0 0
Pretax Income (2.9M) (14.02M) (11.34M) (6.23M) (9.5M)
Income Tax - - 0 0 0
Income Tax - Current Domestic - - 0 - -
Income Tax - Current Foreign - - 0 - -
Income Tax - Deferred Domestic - - 0 - -
Income Tax - Deferred Foreign - - 0 - -
Income Tax Credits - - 0 - -
Equity in Affiliates - - 0 0 0
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income (2.9M) (14.02M) (11.34M) (6.23M) (9.5M)
Minority Interest Expense - - 0 0 0
Net Income (2.9M) (14.02M) (11.34M) (6.23M) (9.5M)
Extraordinaries & Discontinued Operations - - 0 0 0
Extra Items & Gain/Loss Sale Of Assets - - 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations - - 0 0 0
Net Income After Extraordinaries (2.9M) (14.02M) (11.34M) (6.23M) (9.5M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common - - (11.34M) (6.23M) (9.5M)
EPS (Basic) (0.05) (0.18) (0.12) (0.06) (0.07)
Basic Shares Outstanding 61.41M 78.66M 93.05M 97.14M 128.65M
EPS (Diluted) (0.05) (0.18) (0.12) (0.06) (0.07)
Diluted Shares Outstanding 61.41M 78.66M 93.05M 97.14M 128.65M
EBITDA - - (16.09M) (6.54M) (7.94M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.